Barclays PLC Abb Vie Inc. Call Options Transaction History

Barclays PLC

$377 Billion
Q3 2024

Call Options

23 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 15, 2024	SELL	$163.84 - $199.33 $35.7 Million - $43.4 Million	-217,700 Reduced 72.62%	82,100 $16.2 Million
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $36.2 Million - $42.2 Million	233,658 Added 353.27%	299,800 $51.4 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $7.78 Million - $8.86 Million	-48,658 Reduced 42.39%	66,142 $12 Million
Q4 2023 Feb 15, 2024	BUY	$137.6 - $154.97 $15.8 Million - $17.8 Million	114,800 New	114,800 $17.8 Million
Q1 2023 May 04, 2023	SELL	$144.61 - $166.54 $22.9 Million - $26.3 Million	-158,100 Reduced 62.37%	95,400 $15.2 Million
Q4 2022 Feb 13, 2023	BUY	$138.31 - $165.87 $30.2 Million - $36.2 Million	218,100 Added 616.1%	253,500 $41 Million
Q3 2022 Nov 03, 2022	BUY	$134.21 - $153.93 $4.75 Million - $5.45 Million	35,400 New	35,400 $4.75 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $26.5 Million - $33.5 Million	-246,700 Reduced 86.23%	39,400 $5.34 Million
Q2 2021 Aug 13, 2021	SELL	$105.21 - $117.21 $20.7 Million - $23.1 Million	-196,680 Reduced 40.74%	286,100 $32.2 Million
Q4 2020 Feb 11, 2021	BUY	$80.49 - $108.67 $29.1 Million - $39.3 Million	362,000 Added 299.72%	482,780 $51.7 Million
Q3 2020 Nov 12, 2020	SELL	$85.91 - $100.83 $2 Million - $2.35 Million	-23,270 Reduced 16.15%	120,780 $10.6 Million
Q2 2020 Aug 12, 2020	SELL	$73.37 - $98.18 $8.22 Million - $11 Million	-112,050 Reduced 43.75%	144,050 $14.1 Million
Q1 2020 May 13, 2020	SELL	$64.5 - $97.79 $36.7 Million - $55.6 Million	-568,600 Reduced 68.95%	256,100 $19.5 Million
Q4 2019 Feb 10, 2020	BUY	$72.13 - $90.25 $23.1 Million - $28.9 Million	320,500 Added 63.57%	824,700 $73 Million
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $9.38 Million - $11.3 Million	148,900 Added 41.91%	504,200 $38.2 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $9.78 Million - $12.5 Million	148,900 Added 72.14%	355,300 $25.8 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $5.59 Million - $6.58 Million	72,500 Added 54.14%	206,400 $16.6 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $9.51 Million - $11.7 Million	-122,200 Reduced 47.72%	133,900 $12.3 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $4.66 Million - $5.18 Million	-52,400 Reduced 16.99%	256,100 $24.2 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $879,844 - $1.04 Million	9,800 Added 3.28%	308,500 $28.6 Million
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $8.97 Million - $12 Million	97,500 Added 48.46%	298,700 $28.3 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $39.3 Million - $43.1 Million	-439,100 Reduced 68.58%	201,200 $19.5 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $44.7 Million - $57.1 Million	640,300	640,300 $56.9 Million

Others Institutions Holding ABBV

# of Institutions

3,849

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $320B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account